HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test
Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.
Pharma & Biotech
Pharma & Biotech
Why Cartography Biosciences’ Phase 1 colorectal cancer trial matters after Samsung Ventures backing
Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.
Pharma & Biotech
Why Innovent Biologics’ tri-specific IBI3055 matters in the race to deplete both B cells and plasma cells
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
Pharma & Biotech
Can Calidi Biotherapeutics, Inc.’s RedTail platform solve the solid tumor T-cell engager problem?
Calidi Biotherapeutics, Inc. unveils new RedTail and TROP-2 data at AACR 2026. Read what this means for solid tumor immunotherapy and CLD-401 next.
Pharma & Biotech
J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results
FDA approves J&J's teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.